Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe.

Lynn HuynhSteve HassLaurent Peyrin-BirouletMei Sheng DuhHeather SipsmaMu ChengAngie LaxArpita Nag

Published in: Crohn's & colitis 360 (2022)

Infliximab and adalimumab originators dominated first-line biologic therapy for moderate-to-severe UC and CD. Understanding real-world treatment patterns can help assess new treatment uptake and suggest opportunities for improving treatment.

Keyphrases

rheumatoid arthritis
early onset
combination therapy
systemic lupus erythematosus
cross sectional
hidradenitis suppurativa
patients with inflammatory bowel disease